Cost-Effectiveness Analysis of Carfilzomib vs Bortezomib in Relapsed/Refractory Multiple Myeloma in Iran

Value in Health Regional Issues · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles